Advanced Modalities & Therapies
Developers of next-generation approaches such as cell and gene therapies, oligonucleotide and RNA technologies, genomics & proteomics
Strategic perspective on high-value, innovation-driven markets
Assessing Growth in Cell, Gene and Advanced Therapies
Advanced therapies, including cell, gene and RNA-based treatments, are transforming the treatment landscape in oncology, rare diseases and beyond. While scientific progress and regulatory support are accelerating, companies face substantial challenges: high development costs, complex manufacturing, uncertain reimbursement, and competitive pipelines. Investors and management teams must separate genuine opportunity from over-hyped promise.
We help clients evaluate opportunities across this dynamic sector. Our work includes commercial due diligence, transaction support, and growth strategy. We analyse therapeutic pipelines, assess development risk, benchmark valuations against comparable deals, and evaluate reimbursement potential across geographies to test the credibility of investment cases.
Our advanced modalities & therapies leads
Our teams combine deep scientific expertise with commercial and deal experience. We review competitive positioning, regulatory pathways, and manufacturing economics to provide a clear view of both risks and upside. This enables clients to make informed strategic choices in a sector where innovation cycles are rapid and expectations are high.
News & Insights
